Editing Johnson & Johnson (section)

== History ==
=== 1873–1885: Before Johnson & Johnson ===
[[Robert Wood Johnson I|Robert Wood Johnson]] began his professional training at age 16 as a pharmaceutical apprentice at an apothecary run by his mother's cousin, James G. Wood, in Poughkeepsie, New York.<ref>{{Cite news|date=November 12, 2000|title=Carbondale Area Native Founded Johnson & Johnson|pages=129|work=The Times-Tribune|url=https://www.newspapers.com/clip/61974716/carbondale-area-native-founded-johnson/|access-date=October 28, 2020}}</ref><ref name="Rebel">{{Cite book| vauthors = Foster LG |title=The Gentleman Rebel|publisher=Lillian Press|year=1999|isbn=0966288203}}</ref>{{Rp|12}} Johnson co-founded his own company with [[George J. Seabury|George Seabury]] in 1873. The New York-based Seabury & Johnson became known for its medicated plasters.<ref name="bio dictionary">{{Cite book| vauthors = Ingham JN |title=Biographical Dictionary of American Business Leaders|publisher=Greenwood Publishing Group|year=1983|isbn=0313239088|volume= 2}}</ref>{{Rp|675}}<ref name="Rebel"/>{{Rp|15}} Robert Wood Johnson represented the company at the [[Centennial Exposition|1876 World's Fair.]]<ref>{{cite journal | vauthors = Rutkow I | title = Joseph Lister and his 1876 tour of America | journal = Annals of Surgery | volume = 257 | issue = 6 | pages = 1181–7 | date = June 2013 | pmid = 23059499 | doi = 10.1097/SLA.0b013e31826d9116 | s2cid = 389275 }}</ref><ref>{{Cite web|title=World's Fair in Philadelphia : Johnson & Johnson Our Story|url=https://ourstory.jnj.com/worlds-fair-philadelphia|access-date=October 23, 2020|website=ourstory.jnj.com}}</ref> There he heard [[Joseph Lister, 1st Baron Lister|Joseph Lister]]'s explanation of a new procedure: antiseptic surgery.<ref name="Rebel"/>{{Rp|31}} Johnson parted ways with his business partner Seabury in 1885.<ref name="Rebel"/>{{Rp|38}}

=== 1886: Founding of Johnson & Johnson ===
[[File:Robert-wood-johnson-i.jpg|thumb|180px|right|Robert Wood Johnson]]
[[File:Johnson and Johnson corrosive sublimate cotton.jpg|thumb|Early corrosive sublimate cotton packaging with the signature logo]]

Robert Wood Johnson joined his brothers, [[James Wood Johnson]] and [[Edward Mead Johnson]], and created a line of ready-to-use sterile surgical dressings in 1886. They founded Johnson & Johnson in 1886<ref name="bio dictionary"/>{{Rp|675}}<ref name="Rebel"/>{{Rp|38}} with 14 employees, eight women and six men.<ref name="Rebel"/>{{Rp|43}} Johnson & Johnson opened its first factory building in the old Janeway and Carpenter factory on Neilson Street in New Brunswick, New Jersey.<ref>{{Cite news |last=Gordon |first=A. E. |date=March 16, 1994 |title=The New Enterprise |work=The New Brunswick Times}}</ref>
They manufactured sterile surgical supplies, household products, and medical guides.<ref name="History">{{Cite web|title=History of Johnson & Johnson – TheStreet|url=https://www.thestreet.com/personal-finance/history-of-johnson-and-johnson|access-date=October 23, 2020|website=www.thestreet.com|date=February 24, 2020 }}</ref> Those products initially featured a logo that resembled the signature of James Wood Johnson.<ref>{{Cite news| vauthors = Warner S |date=April 10, 2005|title=From Band-Aids To Biotech (Published 2005)|language=en-US|work=[[The New York Times]]|url=https://www.nytimes.com/2005/04/10/nyregion/from-bandaids-to-biotech.html|access-date=October 23, 2020|issn=0362-4331}}</ref> Robert Wood Johnson served as the first president of the company.<ref name="bio dictionary"/>{{Rp|675}}

=== 1887–1942: Early history ===
The company sold medicated plasters such as Johnson & Johnson's Black Perfect Taffeta Court Plaster<ref>{{Cite book|title=Pharmaceutische Rundschau|publisher=Fr. Hoffmann|year=1888|volume=6|location=Harvard University|pages=181}}</ref> and also manufactured the world's first sterile surgical products, including sutures, absorbent cotton, and gauze.<ref>{{Cite book| vauthors = McDonnell G |title=Block's Disinfection, Sterilization, and Preservation|publisher=Lippincott Williams & Wilkins|year=2020|isbn=978-1496381507}}</ref> The company published "Modern Methods of Antiseptic Wound Treatment", a guide on how to do sterile surgery using its products, and in 1888, distributed 85,000 copies to doctors and pharmacists across the United States.<ref name=":3">{{Cite book| vauthors = Pickersgill HE |title=Frederick Barnett Kilmer in History of Middlesex County, New Jersey 1664- 1920|publisher=Lewis Historical Publishing Company|year=1921|location=New York and Chicago}}</ref>{{Rp|3–99}} The manual was translated into three languages and distributed worldwide.<ref name=":3"/> The first commercial [[first aid kit]] was designed in 1888 to support railroad construction workers, who were often hundreds of miles from medical care.<ref name=":3"/> The kits included antiseptic emergency supplies and directions for field use. In 1901, the company published the ''Handbook of First Aid'', a guide on applying first aid.<ref name=":3"/>

In 1889, the company hired pharmacist [[Frederick Barnett Kilmer|Fred Kilmer]] as its first scientific director, who led its scientific research and wrote educational manuals.<ref name=":3" /> Kilmer's first achievement as scientific director was developing the industrial sterilization process.<ref name=":3" /> He was employed at the company until 1934.<ref name=":3" />

Johnson & Johnson had more than 400 employees and 14 buildings by 1894.<ref name=":3" /><ref>{{Cite web|title=1893, 1907, 1929 and Today|url=https://www.kilmerhouse.com/2009/02/1893-1907-1929-and-today|access-date=October 23, 2020|website=Kilmer House|language=en}}</ref> In 1894, the company began producing Johnson's Baby Powder, the company's first baby product.<ref name="History" />

The company introduced the world's first maternity kit in 1894 to aid at-home births, called Dr. Simpson's Maternity Packet, presumably after Scottish [[Obstetrics|obstetrician]] [[James Young Simpson]]. The kit included a washcloth; safety pins; sterile sutures, sponges, and gauze; antiseptic soap; an obstetric sheet and ligatures; flannel to wrap the baby in; and a chart for keeping birth records.<ref>{{Cite web |last=Jenkins |first=Elizabeth |date=May 11, 2017 |title=Oh, Baby! Why Johnson & Johnson Created Dr. Simpson's Maternity Packets |url=https://www.jnj.com/our-heritage/why-johnson-and-johnson-created-dr-simpsons-maternity-packets |access-date=May 24, 2023 |website=Johnson & Johnson}}</ref><ref name="History"/> The products were later marketed separately, including "Lister's Towels", the world's first mass-produced sanitary napkins.<ref>{{Cite web|title=Lister's Towels, Johnson & Johnson, ads at MUM|url=http://www.mum.org/listers.htm|access-date=October 23, 2020|website=www.mum.org}}</ref><ref>{{Cite news|date=February 26, 2020|title=How did companies sell 'unmentionable' sanitary towels?|language=en-GB|work=[[BBC News]]|url=https://www.bbc.com/news/business-51297025|access-date=October 23, 2020}}</ref> Kilmer wrote "Hygiene in Maternity", an instructional guide for mothers before and after delivery.<ref>{{Cite book|url=https://books.google.com/books?id=H8eEF8xhJNgC|title=Red Cross Notes|date=1898|publisher=Johnson & Johnson.|language=en}}</ref> In 1904, the company expanded its baby care products with "Lister's Sanitary Diapers", a diaper product for infants.<ref>{{Cite web|title=Facts about disposable diapers as P&G celebrates 50 years in Cape County|url=https://www.semissourian.com/story/2629488.html|access-date=October 28, 2020|website=Southeast Missourian}}</ref>

During the [[Spanish–American War]], Johnson & Johnson developed and donated 300,000 packaged compressed surgical dressings for soldiers in the field<ref name="Rebel"/>{{Rp|78}} and created a trauma stretcher for field medics. The company donated its products in disaster relief efforts of the [[1900 Galveston hurricane]]<ref name="Rebel"/>{{Rp|79}} and the [[1906 San Francisco earthquake]].<ref name="Rebel"/>{{Rp|81}}

Johnson & Johnson vaccinated all of its employees against [[smallpox]] during the 1901 smallpox epidemic. The firm employed more than 1,200 people by 1910.<ref name="peril">{{Cite news|date=March 28, 1911|title=Peril of City Factories|work=Daily Home News|location=New Brunswick, N.J.}}</ref> Women accounted for half of the company's workforce and led a quarter of its departments.<ref name="peril"/>

Robert Wood Johnson died in 1910, and he was succeeded as president of the company by his brother James Wood Johnson.<ref name="Rebel" />{{Rp|195}}

During [[World War I]], Johnson & Johnson factories increased production to meet wartime demands for sterile surgical products.<ref>{{Cite web|title=World War I Centennial: How the Great War Changed Johnson & Johnson|url=https://www.kilmerhouse.com/2014/08/world-war-i-centennial-how-the-great-war-changed-johnson-johnson|access-date=October 24, 2020|website=Kilmer House|language=en}}</ref><ref name="about us">{{Cite web|title=About Us|url=http://chicopee.com/en-us/about-us|access-date=October 24, 2020|website=Chicopee Solutions|language=en-us}}</ref> In 1916, the company acquired Chicopee Manufacturing Company in [[Chicopee Falls, Massachusetts]], to meet demand.<ref name="about us" /><ref name="Rebel" />{{Rp|129}} Near the end of World War I, the [[Spanish flu|1918 flu pandemic]] broke out. The company invented and distributed an epidemic mask that helped prevent the spread of the flu.<ref>{{Cite web|title=Epidemic Mask – Johnson & Johnson Our Story|url=https://ourstory.jnj.com/epidemic-mask|access-date=October 24, 2020|website=ourstory.jnj.com|archive-date=November 29, 2020|archive-url=https://web.archive.org/web/20201129164657/https://ourstory.jnj.com/epidemic-mask|url-status=dead}}</ref><ref name="universe">{{Cite web|title=History of Johnson & Johnson – FundingUniverse|url=http://www.fundinguniverse.com/company-histories/johnson-johnson-history/|access-date=October 24, 2020|website=www.fundinguniverse.com}}</ref>

In 1919, Johnson & Johnson opened the Gilmour Plant near Montreal, its first factory outside the United States,<ref name="universe"/> which produced surgical products for international customers. In 1924 the company's first overseas manufacturing facility was opened in [[Slough, England|Slough]], England.<ref name="universe"/>

In 1920, Earle Dickson combined two Johnson & Johnson products, adhesive tape and gauze, to create the first commercial adhesive bandage. Band-Aid Brand Adhesive Bandages began sales the following year.<ref name="universe"/><ref name="Rebel"/> In 1921, the company released Johnson's Baby Soap.<ref>{{Cite book|url=https://books.google.com/books?id=wLU9AQAAMAAJ|title=Marketing Communications|date=1921|language=en}}</ref> Named after its Massachusetts facility, Johnson & Johnson built a textile mill and company town, Chicopee, outside Gainesville, Georgia.<ref name="Rebel"/>{{Rp|170}} In the 1930s, the company expanded operations to Argentina, Brazil, Mexico, and South Africa.<ref>{{Cite web| vauthors = Sengupta N |title=Johnson & Johnson: Caring for People, Worldwide|url=https://www.sdmimd.ac.in/SDMRCMS/cases/CIM2013/5.pdf|access-date=October 8, 2020|website=Shri Dharmasthala Manjunatheshwara Institute for Management Development}}</ref> In 1931, Johnson & Johnson introduced the first prescription contraceptive gel marketed as Ortho-Gynol.<ref>{{Cite web|title=1936 Magazine Print Advertisement Ortho Gynol Feminine Jelly Johnson & Johnson|url=http://www.advintageplus.com/1936-magazine-print-advertisement-ortho-gynol-feminine-jelly-johnson-and-johnson/|access-date=October 23, 2020|website=Advintage Plus|language=en|archive-date=October 26, 2020|archive-url=https://web.archive.org/web/20201026045534/http://www.advintageplus.com/1936-magazine-print-advertisement-ortho-gynol-feminine-jelly-johnson-and-johnson/|url-status=dead}}</ref>

[[Robert Wood Johnson II]] became president of the company in 1932.<ref name="Rebel" />{{Rp|195}}

During The Great Depression Johnson & Johnson kept all its workers employed and raised wages by 5%.<ref name="Rebel" />{{Rp|191}} In 1933, Robert Wood Johnson II wrote a letter to [[Franklin D. Roosevelt]], calling for a federal law to increase wages and reduce hours for all American workers.<ref name="Rebel"/>{{Rp|199}} The company also opened a new facility in Chicago during that period.<ref name="Rebel"/>{{Rp|191}} Johnson wrote and distributed "Try Reality: A Discussion of Hours, Wages, and The Industrial Future" to persuade business leaders to follow his lead, advocating that business is more than profit and that companies have responsibilities to consumers, employees, and society. In "Try Reality", the section titled "An Industrial Philosophy" would later become the company's credo.<ref name="Rebel" />{{Rp|224}}<ref name="universe"/>

In 1935, Johnson's Baby Oil was added to its line of baby products.<ref>{{Cite book |url=https://books.google.com/books?id=T1AEAAAAMBAJ|title=LIFE|date=August 9, 1943|publisher=[[Time (magazine)|Time]]|language=en}}</ref><ref>{{Cite web|title=Old School Products That Still Rock|url=https://www.yahoo.com/lifestyle/old-school-products-that-still-rock-88003401298.html|access-date=October 23, 2020|website=www.yahoo.com|date=June 22, 2014 |language=en-US}}</ref> Both male and female Johnson & Johnson employees were drafted and enlisted during World War II.<ref>{{Cite web|title=First Peacetime Draft Enacted Just Before World War II|url=https://www.defense.gov/Explore/Features/Story/Article/2140942/first-peacetime-draft-enacted-just-before-world-war-ii/|access-date=October 23, 2020|website=U.S. Department of Defense|language=en-US}}</ref><ref>{{Cite web|date=August 15, 2016|title=World War I Draft Registration Cards|url=https://www.archives.gov/research/military/ww1/draft-registration|access-date=October 23, 2020|website=National Archives|language=en}}</ref> The company ensured no one would lose their job when they returned home. Robert Wood Johnson II was appointed head of the Smaller War Plants Corporation in Washington, D.C. His work ensured U.S. factories with under 500 employees were awarded government contracts.<ref>{{Cite web|title=Johnson & Johnson Helped by the Healing Powers of Innovation, the Johnson Family Found a Health-Care Empire Inside the Family Medicine Chest. That's Opened up Endless Opportunities. April 1, 2003|url=https://money.cnn.com/magazines/fsb/fsb_archive/2003/04/01/341012/index.htm|access-date=October 23, 2020|website=money.cnn.com}}</ref><ref>{{Cite news|date=January 31, 1968|title=Robert Wood Johnson, 74, Dies; Chairman of Johnson & Johnson; Founder's Son Led Company until 1963 No. 2 Man on War Production Board (Published 1968)|language=en-US|work=[[The New York Times]]|url=https://www.nytimes.com/1968/01/31/archives/robert-wood-johnson-74-dies-chairman-of-johnson-johnson-founders.html|access-date=October 23, 2020|issn=0362-4331}}</ref>

=== 1943: Credo and going public ===
In 1943, as the company was preparing for its [[initial public offering]] (IPO), Robert Wood Johnson wrote what the company would call, "Our Credo",<ref>{{Cite web|title=Our Credo|url=https://www.jnj.com/credo/|access-date=November 29, 2020|website=Content Lab U.S.|language=en}}</ref> a defining document that has been used to guide the company's decisions over the years.<ref>{{cite web|url=https://www.nj.com/business/2012/04/johnson_johnsons_new_ceo_empha.html |title=Johnson & Johnson's new CEO emphasizes company credo at shareholder's meeting | vauthors = Todd S |website=NJ.com |date=April 26, 2012 |access-date=March 13, 2020}}</ref> The company completed its IPO and became a public company in 1944.<ref>{{cite web|url=https://www.fool.com/investing/2019/12/31/if-you-invested-10000-in-johnson-johnsons-ipo-this.aspx |title=If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now | vauthors = Carmichael T |website=fool.com |date=December 31, 2019 |access-date=March 13, 2020}}</ref>

In 1943, [[Vesta Stoudt]] identified a need for waterproof tape for ammunition boxes in [[World War Two]]. She wrote to [[Franklin D. Roosevelt]] with the idea; the president commissioned Revolite, a subsidiary of Johnson & Johnson at the time, to develop and manufacture a cloth-based adhesive tape.<ref>{{Cite web |date=May 6, 2015 |title=October 24, 1943 – COULDN'T KEEP HER IDEA DOWN {{!}} Chicago Tribune Archive |url=http://archives.chicagotribune.com/1943/10/24/page/1/article/couldnt-keep-her-idea-down/ |access-date=August 30, 2022 |archive-url=https://web.archive.org/web/20150506050728/http://archives.chicagotribune.com/1943/10/24/page/1/article/couldnt-keep-her-idea-down/ |archive-date=May 6, 2015 }}</ref>

=== 1944–1999: Acquisitions and international expansion ===
[[File:Johnson and Johnson Logo.svg|thumb|Variation of logo used from the company's establishment until September 14, 2023.]]
In 1944, the company began selling [[Johnson's Baby]] Lotion. The same year, the company established Ethicon Suture Laboratories. In 1947, G. F. Merson Ltd. was acquired to expand the company's suture business in the United Kingdom. The company was rebranded and absorbed into [[Ethicon]].<ref>{{Cite web |date=January 10, 2016 |title=ETHICON History |url=http://www.ethiconproducts.co.uk/about/ethicon-history |archive-url=https://web.archive.org/web/20160110154950/http://www.ethiconproducts.co.uk/about/ethicon-history |archive-date=January 10, 2016  |access-date=August 30, 2022 }}</ref>

Johnson & Johnson [[Chairperson|chairman of the board]], Robert Wood Johnson, published ''Or Forfeit Freedom'', in 1947. The book outlined that businesses need to develop [[Sustainability|sustainable]] methods of using [[natural resource]]s for the future of business and the planet.<ref>{{Cite web |title=Robert Wood Johnson II Writes Or Forfeit Freedom {{!}} Johnson & Johnson Our Story |url=https://ourstory.jnj.com/johnson-writes-or-forfeit-freedom |access-date=August 30, 2022 |website=ourstory.jnj.com}}</ref>

In 1955, Ethicon developed a micro-point reverse-cutting ophthalmic needle attached to the suture. Micro-point surgical needles and sutures allowed for advances in modern vision surgery.<ref>{{Cite web |date=December 3, 2014 |title=A Comparison of Suturing Needles Available |url=https://www.theapprenticedoctor.com/comparison-different-suturing-needles-available-today/ |access-date=August 30, 2022 |website=The Apprentice Doctor |language=en-US}}</ref><ref>{{Cite journal |last1=Byrne |first1=Miriam |last2=Aly |first2=Al |date=March 14, 2019 |title=The Surgical Needle |url=https://pubmed.ncbi.nlm.nih.gov/30869752/ |journal=Aesthetic Surgery Journal |volume=39 |issue=Suppl_2 |pages=S73–S77 |doi=10.1093/asj/sjz035 |issn=1527-330X |pmid=30869752}}</ref> In 1956, the company opened its first Asia-based operating company in the Philippines.<ref>{{Cite web |title=Johnson & Johnson Expands to the Philippines {{!}} Johnson & Johnson Our Story |url=https://ourstory.jnj.com/johnson-johnson-expands-philippines |access-date=August 30, 2022 |website=ourstory.jnj.com}}</ref> The following year, an operating company opened in India.<ref>{{Cite web |title=Expanding to India {{!}} Johnson & Johnson Our Story |url=https://ourstory.jnj.com/expanding-india |access-date=August 30, 2022 |website=ourstory.jnj.com}}</ref><ref>{{Cite web |title=Johnson & Johnson Private Limited – Manufacturer from Jogeshwari (E), Mumbai, India {{!}} About Us |url=https://www.indiamart.com/jnj-india/profile.html |access-date=August 30, 2022 |website=www.indiamart.com}}</ref><ref>{{Cite web |last=Check |first=The Company |title=Johnson & Johnson Private Limited – Company Details {{!}} The Company Check |url=https://www.thecompanycheck.com/company/johnson-johnson-private-limited/U33110MH1957PTC010928 |access-date=August 30, 2022 |website=www.thecompanycheck.com |language=en-IN}}</ref>

In 1959, Johnson & Johnson acquired McNeil Laboratories.<ref name=":0">{{Cite web |date=February 26, 2021 |title=A history of Johnson & Johnson |url=https://pharmaphorum.com/views-analysis-sales-marketing/a-history-of-johnson-johnson/ |access-date=August 30, 2022 |website=pharmaphorum.com |language=en-GB}}</ref> A year later, the company sold Tylenol for the first time without a prescription.<ref name=":0" /> In the same year, Cilag Chemie joined Johnson & Johnson as Cilag.<ref name=":0" /> 

In 1961, Johnson & Johnson acquired [[Janssen Pharmaceuticals]], which had been founded in 1953 by Belgian scientist [[Paul Janssen]],<ref name=":0" /> the inventor of [[Fentanyl]].<ref>{{Cite web |date=2024-02-06 |url=https://www.npr.org/sections/health-shots/2019/09/04/757089868/fentanyl-as-a-dark-web-profit-center-from-chinese-labs-to-u-s-streets#:~:text=On%20how%20Belgian%20physician%20Paul%20Janssen%20invented%20fentanyl&text=He%20started%20his%20own%20company,is%20also%20a%20medical%20drug. | website=[[NPR]] |title=Fentanyl As A Dark Web Profit Center, From Chinese Labs To U.S. Streets}}</ref>

In 1963, [[Philip B. Hofmann]] succeeded Robert Wood Johnson as chairman and CEO. He was the first non-Johnson family member to become chief executive. Hofmann also helped found the [[Robert Wood Johnson Foundation]].<ref name=":1" /> In the same year, the Food and Drug Administration approved a synthetic hormone contraceptive pill, Ortho-Novum.<ref>{{Cite web |title=Ortho-Novum Oral Contraceptive |url=https://americanhistory.si.edu/collections/search/object/nmah_557425 |access-date=August 30, 2022 |website=National Museum of American History |language=en}}</ref>

In 1965, Johnson & Johnson acquired Codman & Shurtleff. The acquired company produced neurovascular devices and neurosurgery technologies.<ref>{{Cite web |last=Winokoor |first=Charles |title=Johnson & Johnson's Codman & Shurtleff surgical instrument line sold to Indiana company |url=https://www.tauntongazette.com/story/entertainment/movies/2011/12/19/johnson-johnson-s-codman-shurtleff/38263438007/ |access-date=August 30, 2022 |website=Taunton Daily Gazette |language=en-US}}</ref> In 1968, the company developed the [[Rho(D) immune globulin|RhoGAM]] vaccine. The vaccine prevented Rh hemolytic disease in newborns.<ref>{{Cite web |date=February 22, 2018 |title=RhoGAM at 50: A Columbia Drug Still Saving Lives of Newborns |url=https://www.cuimc.columbia.edu/news/rhogam-50-columbia-drug-still-saving-lives-newborns |access-date=August 30, 2022 |website=Columbia University Irving Medical Center |language=en}}</ref>

In 1969, Ortho Diagnostics, a company subsidiary, launched the Sickledex Tube Test for detecting anemia.<ref>{{Cite journal |last1=Henry |first1=R. L. |last2=Nalbandian |first2=R. M. |last3=Nichols |first3=B. M. |last4=Camp |first4=F. R. |last5=Conte |first5=N. F. |last6=Wolf |first6=P. L. |date=April 1, 1971 |title=Modified Sickledex tube test: a specific test for S hemoglobin |url=https://www.sciencedirect.com/science/article/pii/S0009912071915049 |journal=Clinical Biochemistry |language=en |volume=4 |issue=1 |pages=196–207 |doi=10.1016/S0009-9120(71)91504-9 |pmid=5143535 |issn=0009-9120}}</ref> The same year, the FDA approved the Johnson & Johnson arterial graft.<ref>{{Cite web |date=August 8, 2021 |title=Coronary Artery Bypass Graft Surgery |url=https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/coronary-artery-bypass-graft-surgery |access-date=August 30, 2022 |website=www.hopkinsmedicine.org |language=en}}</ref> In 1971, the company launched Hapindex Diagnostic Test, a rapid [[hepatitis B]] test for blood donors. The test was developed to prevent the spread of hepatitis B through blood transfusions.<ref>{{Cite journal |last1=Caul |first1=E. O. |last2=Roberts |first2=P. C. |date=December 1974 |title=An evaluation of low voltage counterimmuno-electrophoresis for the detection of hepatitis-B antigen (HB Ag) |journal=Journal of Clinical Pathology |volume=27 |issue=12 |pages=990–993 |doi=10.1136/jcp.27.12.990 |issn=0021-9746 |pmid=4156037|pmc=475570 }}</ref>

In the 1970s, Johnson & Johnson hired Henry N. Cobb from Pei Cobb Freed & Partners to design its new headquarters.<ref>{{Cite web |title=Learning from our Late-Modern Legacy |url=http://www.docomomo-us.org/news/learning-from-our-late-modern-legacy |access-date=2023-06-22 |website=www.docomomo-us.org |language=en}}</ref> The firm designed Johnson & Johnson Plaza across the railroad tracks from the older section of the Johnson & Johnson campus.<ref>{{Cite book |last1=Dorothea |first1=Berkhout |title=New Brunswick, New Jersey, The Decline and Revitalization of Urban America |last2=Listokin |first2=David |last3=Hughes |first3=James |publisher=Rutgers University Press |year=2016 |isbn=978-0813575148}}</ref>

In 1973, [[Richard B. Sellars|Richard Sellars]] became chairman and CEO of Johnson & Johnson.<ref>{{Cite news |last=Abelson |first=Reed |date=June 27, 2010 |title=Richard B. Sellars, Former Chief of Johnson & Johnson, Dies at 94 |language=en-US |work=[[The New York Times]] |url=https://www.nytimes.com/2010/06/27/business/27sellars.html |access-date=August 30, 2022 |issn=0362-4331}}</ref> In 1976, [[James E. Burke]] became the company's chairman and CEO.<ref name=":0"/> During Burke's tenure, he managed the [[Chicago Tylenol murders|1982 Tylenol tampering incident]]. It became a case study on crisis management. Under his leadership, the company recalled 31 million bottles of Tylenol, relaunched the product with a triple tamper-evident seal, and urged consumers not to use if tampered with. These practices became the pharmaceutical and packaged food industry norm.<ref>{{Cite news |last=Hilts |first=Philip J. |date=November 12, 1982 |title=Tylenol Is Reintroduced In Triple-Sealed Package |language=en-US |newspaper=[[The Washington Post]] |url=https://www.washingtonpost.com/archive/politics/1982/11/12/tylenol-is-reintroduced-in-triple-sealed-package/1831aa9c-be08-4c93-a4de-b54e8c0428ed/ |access-date=August 30, 2022 |issn=0190-8286}}</ref>

Johnson & Johnson opened operating companies in China and Egypt in 1985.<ref name=":0"/> In 1987, [[Acuvue]] [[contact lens]]es became the first disposable contact lenses available to consumers. The lenses lasted up to one week, reducing the cost of contact lenses. In the same year, the company launched One Touch, a blood glucose monitoring system. In 1989, [[Ralph S. Larsen]] was appointed chairman and CEO of the company.<ref>{{Cite web |date=October 20, 2012 |title=Ralph S. Larsen – Robert Wood Johnson Foundation |url=http://www.rwjf.org/en/about-rwjf/leadership-staff/board-of-trustees/ralph-s--larsen.html |archive-url=https://web.archive.org/web/20121020073724/http://www.rwjf.org/en/about-rwjf/leadership-staff/board-of-trustees/ralph-s--larsen.html |archive-date=October 20, 2012  |access-date=August 30, 2022 }}</ref>

After the [[dissolution of the Soviet Union]], Johnson & Johnson expanded into eastern Europe. By 1991, the company had a presence in Hungary, Russia, the [[Czech Republic]], and Poland.<ref>{{Cite web |title=Johnson & Johnson Reaches Eastern Europe {{!}} Johnson & Johnson Our Story |url=https://ourstory.jnj.com/johnson-johnson-reaches-eastern-europe |access-date=August 30, 2022 |website=ourstory.jnj.com}}</ref> In the 1990s, the company acquired many familiar consumer health brands that made up the Johnson & Johnson family of companies. These acquisitions included [[Clean & Clear]], [[Neutrogena]], [[Motrin]], and [[Aveeno]].<ref name=":1">{{Cite web |title=History of Johnson & Johnson – FundingUniverse |url=http://www.fundinguniverse.com/company-histories/johnson-johnson-history/ |access-date=August 30, 2022 |website=www.fundinguniverse.com}}</ref>

Johnson & Johnson opened an operating company in Israel in 1996.<ref>{{Cite web |title=Johnson & Johnson Opens in Israel {{!}} Johnson & Johnson Our Story |url=https://ourstory.jnj.com/johnson-johnson-opens-israel |access-date=August 30, 2022 |website=ourstory.jnj.com}}</ref> In 1997, Johnson & Johnson acquired Biosense Webster. [[DePuy Synthes|DePuy]] was acquired by Johnson & Johnson in 1998, rolling it into the Medtech business group.<ref name=":1" />

=== 2000–present ===
[[William C. Weldon]] was appointed chairman and CEO of the company in 2002.<ref>{{Cite news |date=February 21, 2012 |title=Johnson & Johnson CEO Weldon to step down in April |language=en |work=[[Reuters]] |url=https://www.reuters.com/article/us-johnsonjohnson-idUSTRE81K1YO20120221 |access-date=August 30, 2022}}</ref> In 2003, Ethicon launched [[Vicryl]] Plus Antibacterial Sutures. The products prevent post-surgery infection within stitches. In 2006, Johnson & Johnson acquired Pfizer's consumer healthcare business and merged it with its consumer healthcare business group. The acquisition added brands like [[Listerine]], [[Bengay]], and [[Neomycin/polymyxin B/bacitracin|Neosporin]] to the company's portfolio.<ref>{{Cite web |date=June 27, 2006 |title=J&J Buys Pfizer Consumer Healthcare Biz for $16.6 Billion |url=https://www.chiefmarketer.com/jj-buys-pfizer-consumer-healthcare-biz-for-16-6-billion/ |access-date=August 30, 2022 |website=Chief Marketer |language=en-US}}</ref> In the same year, Johnson & Johnson's Janssen Pharmaceuticals, launched [[Prezista]], a protease inhibitor for patients with failed previous HIV therapies.<ref>{{Cite news |date=April 4, 2007 |title=AIDS drug Prezista performs well in new study |language=en |work=[[Reuters]] |url=https://www.reuters.com/article/idUSN04342271 |access-date=November 7, 2022}}</ref><ref>{{Cite web |title=J&J's 800mg Prezista launched in UK – Pharmaceutical industry news |url=https://www.thepharmaletter.com/article/j-j-s-800mg-prezista-launched-in-uk |access-date=November 7, 2022 |website=www.thepharmaletter.com}}</ref>

In 2008, Johnson & Johnson acquired [[Mentor (company)|Mentor Corporation]] for $1&nbsp;billion and merge its operations into Ethicon. In 2009, the company acquired HealthMedia, later renamed to Health & Wellness Solutions and the Human Performance Institute. In October 2010, J&J acquired [[Janssen Vaccines|Crucell]] for $2.4&nbsp;billion. The subsidiary operates as the centre for vaccines, within Johnson & Johnson pharmaceuticals business group.<ref>{{Cite web |title=Johnson & Johnson Acquires Vaccine Developer Crucell |url=https://www.biopharminternational.com/view/johnson-johnson-acquires-vaccine-developer-crucell |access-date=November 7, 2022 |website=BioPharm International |date=March 8, 2011 |language=en}}</ref>

In 2012, [[Alex Gorsky]] became chairman and CEO of Johnson & Johnson.<ref>{{Cite web |last=Murphy |first=Tom |title=J&J CEO Gorsky to step down, company veteran to lead in 2022 |url=https://abcnews.go.com/Health/wireStory/jj-ceo-gorsky-step-company-veteran-lead-2022-79559098 |access-date=August 30, 2022 |website=[[ABC News (United States)|ABC News]] |language=en}}</ref> In November 2015, Biosense Webster, Inc. acquired Coherex Medical Inc. expanding the company's range of treatment options for patients with atrial fibrillation.<ref>{{Cite web |last=Perriello |first=Brad |date=November 20, 2015 |title=J&J's Biosense Webster buys Coherex Medical and its WaveCrest anti-stroke device |url=https://www.massdevice.com/jjs-biosense-webster-buys-coherex-medical/ |access-date=November 7, 2022 |website=MassDevice |language=en-US}}</ref>

In 2017, Johnson & Johnson acquired Abbott Medical Optics from Abbott Laboratories for $4.325&nbsp;billion, adding the new division into [[Johnson & Johnson Vision]] Care, Inc. in 2017.<ref>{{Cite web |title=Johnson & Johnson Vision to acquire TearScience |url=https://www.healio.com/news/ophthalmology/20170804/johnson-johnson-vision-to-acquire-tearscience |access-date=August 30, 2022 |website=www.healio.com |language=en}}</ref> That same year, Johnson & Johnson acquired [[Actelion]] in a $30&nbsp;billion deal, the largest ever purchase by the company. After the purchase, Johnson & Johnson spun off Actelion's research and development unit into a separate legal entity.<ref>{{Cite news |date=January 26, 2017 |title=Johnson & Johnson refills drug cabinet with $30 billion Actelion deal |language=en |work=[[Reuters]] |url=https://www.reuters.com/article/us-actelion-johnson-johnson-idUSKBN15A0KM |access-date=August 30, 2022}}</ref> In July 2017, Johnson & Johnson Vision Care, Inc acquired [[TearScience]]. In September 2017, the company acquired subscription-based contact lens startup Sightbox. In September of the same year Johnson & Johnson Medical GmbH acquired Emerging Implant Technologies GmbH, manufacturer of 3D-printed titanium interbody implants for [[spinal fusion]] surgery.<ref>{{Cite web |title=Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants |url=https://www.biospace.com/article/johnson-and-amp-johnson-medical-gmbh-acquires-emerging-implant-technologies-gmbh-to-enhance-global-offering-of-interbody-spine-implants/ |access-date=August 30, 2022 |website=BioSpace |language=en-US |archive-date=October 3, 2022 |archive-url=https://web.archive.org/web/20221003194540/https://www.biospace.com/article/johnson-and-amp-johnson-medical-gmbh-acquires-emerging-implant-technologies-gmbh-to-enhance-global-offering-of-interbody-spine-implants/ |url-status=dead }}</ref>

In March 2019, the FDA approved [[esketamine]] for the treatment of severe depression, which is marketed as [[Spravato]] by Janssen Pharmaceuticals.<ref>{{Cite web |last=Commissioner |first=Office of the |date=March 24, 2020 |title=FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified |access-date=August 30, 2022 |website=FDA |language=en}}</ref><ref>{{Cite web |date=January 29, 2019 |title=SPRAVATO – Overview |url=https://www.janssencarepath.com/hcp/spravato |access-date=August 30, 2022 |website=Janssen CarePath |language=en}}</ref> In 2019, Johnson & Johnson announced the release of photochromic contact lenses. The lenses adjust to sunlight and help eyes recover from bright light exposure faster. The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives.<ref>{{Cite web |last=Research |first=National Center for Toxicological |date=March 24, 2020 |title=FDA clears first contact lens with light-adaptive technology |url=https://www.fda.gov/news-events/press-announcements/fda-clears-first-contact-lens-light-adaptive-technology |access-date=August 30, 2022 |website=FDA |language=en}}</ref>

In November 2020, Johnson & Johnson acquired Momenta Pharmaceuticals for $6.5&nbsp;billion.<ref>{{Cite news |date=August 19, 2020 |title=Johnson & Johnson to buy biotech Momenta in $6.5bn deal |work=[[Financial Times]]|url=https://www.ft.com/content/9ecd1edc-5709-4264-842b-3c7d2d75f801 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/9ecd1edc-5709-4264-842b-3c7d2d75f801 |archive-date=December 10, 2022 |url-access=subscription |url-status=live |access-date=August 30, 2022}}</ref>

In January 2022, [[Joaquin Duato]] became CEO of Johnson & Johnson.<ref>{{Cite web |first1=Amanda | last1=Macias | first2=Berkeley Jr. | last2 = Lovelace |title=J&J names Joaquin Duato as CEO effective Jan 3, replacing Alex Gorsky |url=https://www.cnbc.com/2021/08/19/jj-names-joaquin-duato-as-ceo-effective-january-3-replacing-alex-gorsky.html |access-date=August 30, 2022 |website=[[CNBC]] | date=August 19, 2021 |language=en}}</ref>

In December 2022, Johnson & Johnson acquired cardiovascular medical technology company [[Abiomed|Abiomed Inc.]] for $16.6&nbsp;billion.<ref>{{cite web|url=https://www.abiomed.com/about-us/news-and-media/press-releases/johnson-and-johnson-completes-acquisition-of-abiomed |title=Johnson & Johnson Completes Acquisition of Abiomed |website=Abiomed.com |date=December 22, 2022}}</ref><ref>{{Cite web |last=Whooley |first=Sean |date=December 22, 2022 |title=Johnson & Johnson completes $16.6B Abiomed acquisition |url=https://www.massdevice.com/johnson-johnson-completes-16-6b-abiomed-acquisition/ |access-date=December 22, 2022 |website=MassDevice |language=en-US}}</ref>

Johnson & Johnson began the separation of their consumer healthcare business segment in November 2021.<ref>{{Cite web |last=Stych |first=Anne |date=September 30, 2022 |title=Johnson & Johnson unveils new name for planned consumer products spinoff |url=https://www.bizjournals.com/bizwomen/news/latest-news/2022/09/johnson-johnson-unveils-rebrand-for-planned-cons.html?page=all |access-date=2023-08-29 |website=www.bizjournals.com}}</ref> In the split, Johnson & Johnson will retain the Johnson & Johnson name for [[prescription drug]]s and [[medical device]]s, while the second company will sell consumer health products and take over the [[Neutrogena]], [[Aveeno]], [[Tylenol_(brand)|Tylenol]], [[Listerine]], Johnson's, [[Band-Aid]] and other brands.<ref>{{Cite web|lang=en|url=https://www.cbsnews.com/news/johnson-johnson-split-two-companies/|title=Johnson & Johnson to split into two companies|website=CBS News|access-date=2024-02-25|archive-date=2022-03-30|archive-url=https://web.archive.org/web/20220330110642/https://www.cbsnews.com/news/johnson-johnson-split-two-companies/}}</ref> In September 2022, Johnson & Johnson chose [[Kenvue]] as the new name for its Consumer Health business. Kenvue went public through an IPO in May 2023, with Johnson & Johnson maintaining a controlling stake of around 91 percent.<ref>{{Cite web |last=Constantino |first=Annika Kim |date=2023-05-04 |title=J&J's consumer-health spinoff Kenvue jumps 22% in public market debut |url=https://www.cnbc.com/2023/05/04/jj-kenvue-ipo-kvue-starts-trading-on-nyse.html |access-date=2023-08-29 |website=[[CNBC]] |language=en}}</ref> On July 24, 2023, Johnson & Johnson launched an exchange offer to split-off Kenvue.<ref>{{Cite news |date=2023-07-24 |title=J&J starts share exchange offer for consumer health spin-off Kenvue |language=en |work=[[Reuters]] |url=https://www.reuters.com/business/healthcare-pharmaceuticals/jj-begins-share-exchange-offer-consumer-health-spin-off-kenvue-2023-07-24/ |access-date=2023-08-29}}</ref> Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.<ref>{{Cite web |last=Whooley |first=Sean |date=2023-08-23 |title=Johnson & Johnson finalizes Kenvue spilt-off |url=https://www.massdevice.com/johnson-johnson-finalizes-kenvue-spilt-off/ |access-date=2023-08-29 |website=MassDevice |language=en-US}}</ref>In 2024, Johnson & Johnson sold off its remaining 9.5% stake in Kenvue, its former consumer products business.<ref>{{Cite web |title=Johnson & Johnson Financial Statements 2009-2025 {{!}} JNJ |url=https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/financial-statements |access-date=2025-03-29 |website=www.macrotrends.net}}</ref>

Johnson & Johnson holds a patent on the tuberculosis-treating drug [[bedaquiline]], with secondary patents in at least 25 out of 43 countries with a high burden of tuberculosis blocking affordable generic versions of the drug, preventing millions of people from accessing the life-saving treatment.<ref>{{Cite web |date=April 26, 2023 |title=MSF: J&J must stop blocking generic versions of lifesaving TB drug |url=https://www.doctorswithoutborders.org/latest/msf-jj-must-stop-blocking-generic-versions-lifesaving-tb-drug |access-date=2023-07-13 |website=Doctors Without Borders – USA |language=en}}</ref><ref>{{Cite web |last=((The Wire Staff)) |date=2023-03-23 |title=J&J's Application to Extend Patent on Anti-Tuberculosis Drug Bedaquiline Rejected |url=https://thewire.in/health/johnson-and-johnson-patent-tuberculosis-drug-bedaquiline |access-date=2023-07-13 |website=The Wire}}</ref> Though the patent was set to expire in many countries in 2023, Johnson & Johnson applied to extend the patent. On July 13, 2023, [[Stop TB Partnership]] announced that after negotiations with Johnson & Johnson, they had been granted licenses to produce generic versions of the drug.<ref>{{Cite web |title=Global Drug Facility Update on Access to Bedaquiline {{!}} Stop TB Partnership |url=https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline |access-date=2023-09-10 |website=www.stoptb.org}}</ref>

Johnson & Johnson announced several acquisitions in 2024: Ambrx Biopharma for $2 billion (in January),<ref>{{Cite web |last=Constantino |first=Annika Kim |date=2024-01-08 |title=J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion |url=https://www.cnbc.com/2024/01/08/jj-to-acquire-ambrx-biopharma-a-cancer-drug-developer.html |access-date=2024-01-09 |website=CNBC |language=en}}</ref> Shockwave Medical for $13.1 billion (in April),<ref>{{Cite web |date=2024-04-05 |title=Johnson & Johnson boosts heart device business with $12.5 billion Shockwave Medical deal |url=https://www.cnbc.com/2024/04/05/johnson-johnson-to-buy-shockwave-medical-for-12point5-billion.html |access-date=2024-04-05 |website=CNBC |language=en}}</ref><ref>{{Cite web |date=2024-04-05 |title=Johnson & Johnson to Acquire Shockwave Medical |url=https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-shockwave-medical |access-date=2024-04-10 |website=JNJ.com |language=en-US}}</ref><ref>{{Cite news |last=Loftus |first=Colin Kellaher and Peter |title=Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal |url=https://www.wsj.com/health/pharma/johnson-johnson-to-buy-shockwave-medical-in-13-1-billion-deal-5c3a45ce |access-date=2024-04-10 |work=WSJ |language=en-US}}</ref> and Proteologix for $850 million (in May).<ref>{{Cite web |date=2024-05-16 |title=J&J Buys Proteologix for $850M, Bispecific Antibodies for Atopic Dermatitis |url=https://www.biospace.com/j-and-j-buys-proteologix-for-850m-secures-bispecific-antibodies-targeting-atopic-dermatitis?s=79 |access-date=2024-08-16 |website=BioSpace |language=en-US}}</ref> In 2024, Johnson & Johnson MedTech released Polyphonic, a digital surgical platform. The platform features surgery planning, surgical video, and telepresence services for laparoscopic surgeries.<ref>{{Cite web |title=J&J creates open digital platform for surgical applications {{!}} MedTech Dive |url=https://www.medtechdive.com/news/johnson-open-digital-platform-surgical-applications/719481/ |access-date=2025-03-26 |website=www.medtechdive.com |language=en-US}}</ref>

Johnson & Johnson announced it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion.<ref>{{Cite web |date=2025-01-13 |title=J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion |url=https://www.cnbc.com/2025/01/13/jj-jnj-to-buy-intra-cellular-therapies-itci.html |access-date=2025-01-13 |website=CNBC |language=en}}</ref>

==== Coronavirus (COVID-19) response ====
Johnson & Johnson committed over $1&nbsp;billion toward the development of a not-for-profit [[COVID-19]] vaccine&nbsp;in partnership with the [[Biomedical Advanced Research and Development Authority]] (BARDA) Office of the [[Assistant Secretary for Preparedness and Response]] (ASPR) at the [[U.S. Department of Health and Human Services]] (HHS).<ref name="Vecchione">{{Cite web|url=https://njbiz.com/jj-collaborates-accelerate-covid-19-vaccine-development/|title=J&J collaborates to accelerate COVID-19 vaccine development|last=Vecchione|first=Anthony|date=March 13, 2020|website=NJBIZ|language=en-US|access-date=April 22, 2020}}</ref><ref>{{Cite web|url=https://www.wspa.com/news/prisma-health-collaborates-with-ethicon-inc-to-make-distribute-vesper-ventilator-expansion-splitter-device/|title=Prisma Health collaborates with Ethicon Inc. to make, distribute VESper Ventilator Expansion Splitter Device|date=April 6, 2020|website=WSPA 7News|language=en-US|access-date=April 22, 2020|archive-date=January 22, 2021|archive-url=https://web.archive.org/web/20210122191226/https://www.wspa.com/news/prisma-health-collaborates-with-ethicon-inc-to-make-distribute-vesper-ventilator-expansion-splitter-device/|url-status=dead}}</ref> Paul Stoffels of Johnson & Johnson said, "In order to go fast, the people of Johnson & Johnson are committed to do this and all together we say we're going to do this not for profit. That's the fastest and the best way to find all the collaborations in the world to make this happen so we commit to bring this at a not-for-profit level."<ref>{{Cite web|url=https://news.sky.com/story/coronavirus-johnson-johnson-vows-to-make-not-for-profit-vaccine-11966292|title=Coronavirus: Johnson & Johnson vows to make 'not-for-profit' vaccine|website=Sky News|language=en|access-date=April 22, 2020}}</ref>

[[Crucell|Janssen Vaccines]], in partnership with [[Beth Israel Deaconess Medical Center]] (BIDMC), is responsible for developing the vaccine candidate, based on the same technology used to make its [[Ebola vaccine]]. The vaccine candidate is expected to enter phase 1 human clinical study in September 2020.<ref name="Vecchione"/><ref>{{Cite web|url=https://www.cnbc.com/2020/03/17/jj-hopes-to-start-human-trials-for-coronavirus-vaccine-in-november.html|title=J&J hopes to start human trials for coronavirus vaccine in November |last=Stankiewicz |first=Kevin |date=March 17, 2020 |website=[[CNBC]] |language=en |access-date=April 22, 2020}}</ref><ref>{{Cite web|url=https://njbiz.com/jj-collaborates-accelerate-covid-19-vaccine-development/|title=J&J collaborates to accelerate COVID-19 vaccine development |last=Vecchione |first=Anthony |date=March 13, 2020 |website=NJBIZ |language=en-US |access-date=April 22, 2020}}</ref>

Demand for the product [[Tylenol (brand)|Tylenol]] surged two to four times normal levels in March 2020. In response, the company increased production globally. For example, the Tylenol plant in Puerto Rico ran 24 hours a day, seven days a week.<ref>{{Cite news|url=https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-idUSKBN2162FU|title=J&J's Tylenol production at maximum capacity as coronavirus boosts demand|date=March 19, 2020|work=[[Reuters]]|access-date=April 22, 2020|language=en}}</ref>

In response to the shortage of ventilators, Ethicon, with [[Prisma Health]], made and distributed the VESper Ventilator Expansion Splitter, which uses 3D printing technology, to allow one ventilator to support two patients.<ref>{{Cite web|url=https://www.morningstar.com/news/dow-jones/202004068375/prisma-health-ethicon-to-build-ventilator-split-device-for-emergency-use|title=Prisma Health, Ethicon to Build Ventilator Split Device for Emergency Use|website=www.morningstar.com|language=en|access-date=April 22, 2020|archive-date=January 22, 2021|archive-url=https://web.archive.org/web/20210122175048/https://www.morningstar.com/news/dow-jones/202004068375/prisma-health-ethicon-to-build-ventilator-split-device-for-emergency-use|url-status=dead}}</ref>

==== Janssen COVID-19 vaccine ====
{{main|Janssen COVID-19 vaccine}}
In June 2020, Johnson & Johnson and the [[National Institute of Allergy and Infectious Diseases]] (NIAID) confirmed its intention to start a clinical trials of J&J's vaccine in September 2020, with the possibility of Phase 1/2a human clinical trials starting at an accelerated pace in the second half of July.<ref>{{Cite web|last=Coleman|first=Justine|date=June 10, 2020|title=Final testing stage for potential coronavirus vaccine set to begin in July|url=https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|access-date=June 11, 2020|website=[[The Hill (newspaper)|The Hill]]|language=en}}</ref><ref>{{Cite news|title=Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ|url=https://www.fiercepharma.com/vaccines/nih-preps-late-stage-studies-moderna-az-and-j-j-coronavirus-vaccines-wsj|access-date=June 11, 2020|newspaper=Fierce Pharma|date=June 10, 2020 |language=en}}</ref><ref>{{Cite news|title=Johnson & Johnson to start human testing of COVID-19 vaccine next week|url=https://www.fiercepharma.com/vaccines/j-j-to-start-human-testing-covid-19-vaccine-next-week-exec|access-date=July 20, 2020|newspaper=Fierce Pharma|date=July 16, 2020 |language=en}}</ref>

On August 5, 2020, the [[Federal government of the United States|US government]] agreed to pay more than $1&nbsp;billion to Johnson & Johnson (medical device company) for the production of 100 million doses of COVID-19 vaccine. As part of the agreed-upon deal, the U.S. can order up to 200&nbsp;million additional doses of SARS-CoV-2 vaccine.<ref>{{cite web|url=https://www.voanews.com/a/covid-19-pandemic_us-pay-johnson-and-johnson-1-billion-covid-19-vaccine/6193967.html|title=US to Pay Johnson and Johnson $1 Billion for COVID-19 Vaccine|access-date=August 5, 2020|website=Voice of America|date=August 5, 2020 }}</ref>

In September 2020, Johnson & Johnson started its 60,000-person phase 3 [[Adenoviridae|adenovirus]]-based vaccine trial.<ref>{{Cite press release|last=Johnson|first=Johnson &|title=Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate|url=https://www.prnewswire.com/news-releases/johnson--johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate-301136522.html|access-date=September 24, 2020|website=www.prnewswire.com|language=en}}</ref> The trial was paused on October 12, 2020, because a volunteer became ill,<ref>{{Cite news|last1=Hughes|first1=Virginia|last2=Thomas|first2=Katie|last3=Zimmer|first3=Carl|last4=Wu|first4=Katherine J.|date=October 12, 2020|title=Johnson & Johnson halts coronavirus vaccine trial because of sick volunteer.|language=en-US|work=[[The New York Times]]|url=https://www.nytimes.com/live/2020/10/12/world/coronavirus-covid|access-date=October 12, 2020|issn=0362-4331}}</ref> but the company said it found no evidence that the vaccine had caused the illness and announced on October 23, 2020, that it would resume the trial.<ref>{{Cite web|date=October 23, 2020|title=Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.|url=https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us|access-date=October 28, 2020|website=Johnson & Johnson|language=en}}</ref><ref>{{Cite web|last1=Edwards|first1=Erika|last2=Miller|first2=Sara G.|date=October 23, 2020|title=AstraZeneca, Johnson & Johnson resume late-stage Covid-19 vaccine trials|url=https://www.nbcnews.com/health/health-news/astrazeneca-johnson-johnson-resume-late-stage-covid-19-vaccine-trials-n1244579|access-date=October 28, 2020|website=[[NBC News]]|language=en}}</ref>

In April 2021, the company reported that its COVID-19 vaccine achieved $100&nbsp;million sales in the first quarter, accounting for less than 1% of its total revenue.<ref>{{Cite web|last=Lovelace|first=Berkeley Jr.|date=April 20, 2021|title=Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine|url=https://www.cnbc.com/2021/04/20/johnson-johnson-jnj-earnings-q1-2021.html|access-date=April 29, 2021|website=[[CNBC]]|language=en}}</ref><ref>{{Cite news|last=Grant|first=Charley|date=April 20, 2021|title=Johnson & Johnson Shows Health Economy Is Nearing Full Strength|language=en-US|work=[[The Wall Street Journal]]|url=https://www.wsj.com/articles/johnson-johnson-shows-health-economy-is-nearing-full-strength-11618931401|access-date=April 29, 2021|issn=0099-9660}}</ref>